Voltar
Carta Acesso aberto Produção Nacional
BIBTEX RIS

MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway

2018; AME Publishing Company; Volume: 10; Issue: S16 Linguagem: Inglês

10.21037/jtd.2018.04.122

ISSN

2077-6624

Autores

Ramon Andrade De Mello, Pedro Nazareth Aguiar, Hakaru Tadokoro, Tállita Meciany Farias-Vieira, Pedro Castelo‐Branco, Gilberto Lopes, Daniel Humberto Pozza,

Tópico(s)

PI3K/AKT/mTOR signaling in cancer

Resumo

Non-small cell lung cancer (NSCLC) is still challenging in terms of screening and treatment approaches (1). In Europe, Latin-America and US, NSCLC is among the most common diseases for both men and women (2).

Referência(s)